TrialThe oncologist2025

Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer: safety analysis of FRESCO-2.

Cathy Eng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.